Drug resistance in Cryptococcus neoformans

Drug Resistance Updates

Volumn 2, Issue 4, 1999, Pages 259-269

  Perfect, John R ^a   Cox, Gary M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; PYRROLE DERIVATIVE; VORICONAZOLE;

CRYPTOCOCCUS NEOFORMANS; DRUG DELIVERY SYSTEM; IMMUNOMODULATION; MYCOSIS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; TREATMENT FAILURE;

EID: 0033178120     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.1999.0090     Document Type: Article

References (127)

1. White T. C., Marr K. A., Bowden R. A. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev. 11:1998;382-402.
2. Perfect J. R., Alexander B. D. Antifungal resistance trends towards the year 2000: Implications for therapy and new approaches. Drugs. 54:1997;657-678.
3. Perfect J. R. Cryptococcosis. Infect Dis Clin North Am. 3:1989;77-102.
4. Littman M. L., Zimmerman L. E. Cryptococcosis. Anonymous, Grune & Stratton, 1956;. p. 125-128.
5. Dismukes W. E., Cloud G., Gallis H. A. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med. 317:1987;334-341.
6. van der Horst C., Saag M. S., Cloud G. A. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med. 337:1997;15-21.
7. Perfect J. R., Durack D. T., Hamilton J. D., Gallis H. A. Failure of ketoconazole in cryptococcal meningitis. JAMA. 247:1982;3349-3351.
8. Dismukes W. E., Stamm A. M., Garybill J. R. Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases Collaborative Antifungal Study. Ann Intern Med. 98:1983;13-20.
9. Larsen R. A., Bozzette S., McCutchan A., Chiu J., Leal M. A., Richman D. D. Persistent Cryptococcus neoformans infection of the prostate after successful treatment of meningitis. Ann Intern Med. 111:1989;125-128.
10. Chuck S. L., Sande M. A. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med. 321:1989;794-799.
11. Kovacs J. A., Kovacs A. A., Polis M. Cryptococcosis in the acquired immunodeficiency syndrome. Ann Intern Med. 103:1985;533-538.
12. Eng R. H., Bishburg E., Smith S. M. Cryptococcal infections in patients with acquired immune deficiency syndrome. Am J Med. 81:1986;19-23.
13. Zuger A., Louie E., Holzman R. S., Simberkoff M. S., Rahal J. J. Cryptococcal disease in patients with acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment. Ann Intern Med. 104:1986;234-240.
14. Bozzette S. A., Larsen R. A., Chin J. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. N Engl J Med. 324:1991;580-584.
15. Diamond R. D., Bennett J. E. Prognostic factors in cryptococcal meningitis. A study of 111 cases. Ann Intern Med. 80:1974;176-181.
16. Perfect J. R., Lang S. D. R., Durack D. T. Chronic cryptococcal meningitis: A new experimental model in rabbits. Am J Pathol. 101:1980;177-194.
17. Velez J. D., Allendoerfer R., Luther M., Rinaldi M. G., Graybill J. R. Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis. J Infect Dis. 168:1993;508-510.
18. Mitchell D. H., Sorrell T. C., Allworth A. M. Cryptococcal disease of the CNS in immunocompetent hosts: Influence of cryptococcal variety on clinical manifestations and outcome. Clin Infect Dis. 20:1995;611-616.
19. Speed B., Dunt D. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis. 21:1995;28-34.
20. Kelly S. L., Lamb D. C., Taylor M.E.A., Corran A. J., Baldwin B. C., Powderly W. G. Resistance to amphotericin B associated with defective sterol delta 8-7 isomerase in a Cryptococcus neoformans strain from an AIDS patient. FEMS Microbiol Lett. 122:1994;39-42.
21. Block E. R., Jennings A. E., Bennett J. E. 5-Fluorocytosine resistance in Cryptococcus neofomans. Antimicrob Agents Chemother. 3:1973;649-656.
22. Kerkering T. M., Duma R. J., Shadomy S. The evolution of pulmonary cryptococcosis. Clinical implications from a study of 41 patients with and without compromising host factors. Ann Intern Med. 94:1981;611-616.
23. Armengou A., Porcar C., Mascaro J., Garcia-Bragado F. Possible development of resistance to fluconazole during suppressive therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis. 23:1996;1337-1338.
24. Berg J., Clancy C. J., Nguyen M. H. The hidden danger of primary fluconazole prophylaxis for patients with AIDS. Clin Infect Dis. 26:1998;186-187.
25. Birley H. D., Johnson E. M., McDonald P., Parry C., Carey P. B., Warnock D. W. Azole drug resistance as a cause of clinical relapse in AIDS patients with cryptococcal meningitis. Int J STD and AIDS. 6:1995;353-355.
26. Peetermans W., Bobbaers H., Verhaegen J., Vanderpitte J. Fluconazole-resistant Cryptococcus neoformans var gattii in an AIDS patient. Acta Clin. Belgica. 48:1993;405-409.
27. Prugam A., Dupouy-Camet J., Blanche P., Gangneux J. P., Tourte-Schaefer C., Sicard D. Increased fluconazole resistance of Cryptococcus neoformans isolated from a patient with AIDS and recurrent meningitis. Clin Infect Dis. 19:1994;975-976.
28. Viard J. P., Hennequin C., Fortineau N., Pertuiset N., Rothschild C., Zylberberg H. Fulminant cryptococcal infections in HIV-infected patients on oral fluconazole. Lancet. 346:1995;118.
29. Venkateswarlu K., Taylor M., Manning N. J., Rinaldi M. G., Kelly S. L. Fluconazole tolerance in clinical isolates of Cryptococcus neoformans. Antimicrob Agents Chemother. 41:1997;748-751.
30. Whelan W. L. The genetic basis of resistance to 5-fluorocytosine in Candida species and Cryptococcus neoformans. Crit Rev Microbiol. 15:1987;45-56.
31. Abruzzo G. K., Flattery A. M., Gill C. J. Evaluation of the echinocandin antifungal MK-0991 (L-743, 872): efficacies in mouse models of disseminated Aspergillosis, Candidiasis, and Cryptococcosis. Antimicrob Agents Chemother. 41:1997;2333-2338.
32. Bartizal K., Gill C. J., Abruzzo G. K. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother. 41:1997;2326-2332.
33. Franzot S. P., Casadevall A. Pneumocandin L743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob Agents Chemother. 44:1997;331-336.
34. Davey K. G., Johnson E. M., Holmes A. D., Szekely A., Warnock D. W. In vivo susceptibility of Cryptococcus neoformans isolates to fluconazole and itraconazole. J Antimicrob Chemother. 42:1998;217-270.
35. Koletar S. L., Buesching W. J., Fass R. J. Emerging resistance to fluconazole among blood and CSF Cryptococcus neoformans isolates. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. abstr E70:1995.
36. Anaissie E. J., Paetznick V. L., Ensign L. G. Microdilution antifungal susceptibility testing of Candida albicans and Cryptococcus neoformans with and without aggitation: an eight-center collaborative study. Antimicrob Agents Chemother. 40:1996;2387-2391.
37. Witt M. D., Lewis R. J., Larsen R. A. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: The role of antifungal susceptibility testing. Clin Infect Dis. 22:1996;322-328.
38. Ghannoum M. A., Ibrahim A. S., Fu Y., Shafig M. C., Edwards J. E., Criddle R. S. Susceptibility testing of Cryptococcus neoformans: a microdilution technique. J Clin Microbiol. 30:1992;2881-2886.
39. Lozano-Chiu M., Paetznick V. L., Ghannoum M. A., Rex J. H. Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A Methodologies. J Clin Microbiol. 36:1998;2817-2822.
40. Iwata K., Yamashita T., Ohsumi M. Comparative morphological and biological studies on itraconazole- and ketoconazole-resistant mutants of Cryptococcus neoformans. J Med Vet Mycol. 28:1990;77-90.
41. Currie B., Sanati H., Ibrahim A. S., Edwards J. E., Casadevall A., Ghannoun M. A. Sterol compositions and susceptibilities to amphotericin B of environmental Cryptococcus neoformans isolates are changed by murine passage. Antimicrob Agents Chemother. 39:1995;1934-1937.
42. Thornwell S. J., Peery R. B., Skatrud P. C. Cloning and characterization of CneMDRI: a Cryptococcus neoformans gene encoding a protein related to multidrug resistance proteins. Gene. 201:1997;21-29.
43. Joseph-Horne T., Hollomon D., Loeffler R. S., Kelly S. L. Cross-resistance to polyene and azole drugs in Cryptococcus neoformans. Antimicrob Agents Chemother. 39:1995;1526-1529.
44. Thompson J. R., Douglas C. M., Li N. A glucan synthase FKS1 homolog in cryptococcus is a single copy and encodes an essential function. J Bacteriol. 181:1999;444-453.
45. Joseph-Horne T., Loeffin R., Halloman D. W., Kelly S. L. Amphotericin B resistant isolates of Cryptococcus neoformans without alteration in sterol biosynthesis. J Med Vet Mycol. 34:1996;223-225.
46. Utz J. P., Shadomy S., McGehee R. F. 5-flucytosine: Experience in patients with pulmonary and other forms of cryptococcosis. Am Rev Respir Dis. 99:1969;975-975.
47. Utz J. P., Shadomy S., McGehee R. F. Flucytosine. N Engl J. Med. 286:1972;777-778.
48. Block E. R., Jennings A. E., Bennett J. E. Variables influencing susceptibility testing of Cryptococcus neoformans to 5-fluorocytosine. Antimicrob Agents Chemother. 4:1973;392-395.
49. Hospenthal D. R., Bennett J. E. Flucytosine monotherapy for cryptococcosis. Clin Infect Dis. 27:1998;260-264.
50. Bennett J. E. Flucytosine. Ann Intern Med. 86:1977;319-322.
51. Perfect J. R., Durack D. T., Gallis H. A. Cryptococcemia. Medicine. 62:1983;98-109.
52. Bennett J. E., Dismukes W., Duma R. J. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med. 301:1979;126-131.
53. Saag M. S., Cloud G. A., Graybill J. R. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis. 28:1999.
54. Brandt M. E., Pfaller M. A., Hajjeh R. A. Molecular subtypes and antifungal susceptibilities of serial Cryptococcus neoformans isolates in human immunodeficiency virus-associated cryptococcosis. J Infect Dis. 174:1996;812-820.
55. Spitzer E. D., Spitzer S. G., Freundlich L. F., Casadevall A. Persistence of initial infection in recurrent Cryptococcus neoformans meningitis. Lancet. 341:1993;595-596.
56. Casadevall A., Spitzer E. D., Webb D., Rinaldi M. G. Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole. Antimicrob Agents Chemother. 37:1993;1383-1386.
57. Berry A. J., Rinaldi M. G., Graybill J. R. Use of high dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS. Antimicrob Agents Chemother. 36:1992;690-692.
58. Haubrich R. H., Haghighat D., Bozzette S. A., McCutchan J. A. High dose fluconazole for treatment of cryptococcal disease in patients with human immunodeficiency virus infection. J Infect Dis. 170:1994;238-242.
59. Alves S. H., Lopes J. O., Costa J. M., Klock C. Development of secondary resistance to fluconazole in Cryptococcus neoformans isolated from a patient with AIDS. Revista do Instituto de Medicina Tropical de Sao Paulo. 39:1997;359-361.
60. Lamb D. C., Corran A., Baldwin B. Cea, Kwon-Chung J., Kelly S. L. Resistant P45051 A1 activity in azole antifungal tolerant Cryptococcus neoformans from AIDS patients. FEBS Lett. 368:1995;326-330.
61. Vanden Bossche H., Marichal P., Le June L., Coese M. C., Gorrens J., Cools W. Effects of itraconazole and cytochrome P-450 sterol 14 alpha-demethylation and reduction of 3-ketosteroids in Cryptococcus neoformans. Antimicrob Agents Chemother. 37:1993;2101-2105.
62. Abl-Hanna P., Bennett J. E., Marichal P., Vanden Bossche H., Williamson P. R. Production of high-level fluconazole resistant mutants of Cryptococcus neoformans by signature-tagged mutagenesis. 36th Infectious Disease Society Meetings, Denver. 1998.
63. Davis L. E., Shen J., Roger R. E. In vitro synergism of concentrated allium satiuum extract and amphotericin B against Cryptococcus neoformans. Planta Medica. 60:1994;546-549.
64. Kartalija M., Kaye K., Tureen J. H. Treatment of experimental Cryptococcal meningitis with fluconazole: impact of dose and addition of flucytosine on mycologic and pathophysiologic outcome. J Infect Dis. 173:1996;1216-1221.
65. Viviani M. A., Tortorano A. M., Langer M. Experience with itraconazole in cryptococcosis and aspergillosis. J Infect. 18:1989;151-165.
66. Chen G-H., Curtis J. L., Mody C. H., Christensen P. J., Armstrong L. R., Toews G. B. Effect of granulocyte-macrophage colony-stimulating factor on rat alveolar macrophage anticryptococcal activity in vitro. J Immunol. 152:1994;724-734.
67. Collins H. L., Bancroft G. J. Cytokine enhancement of complement-dependent phagocytosis of macrophages: synergy of tumor necrosis factor alpha and granulocyte macrophage colony stimulating factor for phagocytosis of Cryptococcus neoformans. Eur J Immunol. 22:1992;1447-1454.
68. Price D. A., Klein J. L., Fisher M., Main J., Bingham J. S., Coker R. J. Potential role for granulocyte-macrophage colony-stimulated factor in the treatment of HIV-associated cryptococcal meningitis. AIDS. 11:1997;693-694.
69. Torres I. R., Villareal U. C., Robles R. M., Aparicio P., Cano D. C. Comparative study between two treatment schedules in AIDS patients with meningitis caused by Cryptococcus neoformans. GM-CSF plus amphotericin B versus amphotericin B alone. Anonymous Leucomax. Current Use and Future Applications. 1993;Adelphi Communications, Lucerne. p. 64.
70. Levitz S. M. Activation of human peripheral blood mononuclear cells by interleukin-2 and granulocyte-macrophage colony stimulating factor to inhibit Cryptococcus neoformans. Infection & Immunity. 59:1991;3393-3397.
71. Kowakami K., Tohyama M., Teruya K., Kudeken N., Xie Q., Saito A. Contribution of interferon-gamma in protecting mice during pulmonary and disseminated infection with Cryptococcus neoformans. FEMS Immunol Med Microbiol. 13:1996;123-130.
72. Clemons K. V., Brummer E., Stevens D. A. Cytokine treatment of central nervous system infection: Efficacy of interleukin 12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis. Antimicrob Agents Chemother. 38:1994;460-464.
73. Kawakami K., Tohyama M., Xie Q., Saito A. 1L12 protects mice against pulmonary and disseminated infection caused by Cryptococcus neoformans. Clin Exp Immunol. 104:1996;208-214.
74. Dromer F., Charreire J. Improved amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action. J Infect Dis. 163:1991;1114-1120.
75. Dromer F., Charreire J., Contrepois A., Carbon C., Yeni P. Protection of mice against experimental cryptococcosis by anti- Cryptococcus neoformans monoclonal antibody. Infection & Immunity. 55:1987;749-752.
76. Mukherjee J., Zuckier L. S., Scharff M. D., Casadevall A. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B. Antimicrob Agents Chemother. 38:1994;580-587.
77. Gordon M. A., Casadevall A. Serum therapy of cryptococcal meningitis. Clin Infect Dis. 21:1995;1477-1479.
78. Casadevall A. Antibody-based therapies for emerging infectious diseases. Emerg Infect Dis. 2:1996;200-208.
79. Powderly W. G., Finkelstein D. M., Feinberg J. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Eng J Med. 332:1995;700-705.
80. McKinsey D., Wheat J., Cloud G. Itraconazole prophylaxis against fungal infections in patients with advanced human immunodeficiency virus infection: randomized placebo-controlled double-blind study. Clin Infect Dis. 28:1999;1049-1056.
81. Manfredi R., Moroni A., Mazzoni A. Isolated detection of Cryptococcal polysaccloride antigen in cerebrospinal fluid samples from patients with AIDS. Clin Infect Dis. 23:1996;849-850.
82. Clark J. M., Whitney R. R., Olsen S. J. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother. 35:1991;615-621.
83. Clemons K. V., Stevens D. A. Comparison of fungizone, amphotec, ambisome, and abelcet for treatment of systemic murine cryptococcosis. Antimicrob Agents Chemother. 42:1998;899-902.
84. Hostetler J. S., Clemons K. V., Hanson L. H., Stevens D. A. Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis. Antibiot Chemother. 36:1992;2656-2660.
85. Oppenheim B. A., Herbrecht R., Kusne S. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Mycoses. 21:1995;1145-1153.
86. Perfect J. R., Wright K. A. Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidiasis. J Antimicrob Chemother. 33:1994;73-81.
87. Schurmann D., Marques B., Pohle H. D., Ruf B. Safety and efficacy of liposomal amphotericin B in treating AIDS-associated disseminated cryptococcosis. J Infect Dis. 164:1991;620-622.
88. Sharkey P. K., Graybill J. R., Johnson E. S. Amphotericin B lipid complex compared with amphotericin B in the treatment of Cryptococcal meningitis in patients with AIDS. Clin Infect Dis. 22:1996;315-321.
89. Coker R. J., Viviani M., Gazzard B. G. Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS. 7:1993;829-835.
90. Leenders A. C., Reiss P., Portegies P. Liposomal amphotericin B (Ambisome) compared with amphotericin B followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS. 11:1997;1463-1471.
91. Fujita N. K., Reynard M., Sapico F. L., Guze L. B., Edwards J. E. Jr. Cryptococcal intracerebral mass lesions. Ann Intern Med. 94:1981;382-388.
92. Hammerman K. J., Powell K. E., Christianson C. S. Pulmonary cryptococcosis: Clinical forms and treatment. A Center for Disease Control Cooperative Mycoses Study. Am Rev Respir Dis. 108:1973;1116-1123.
93. Majid A. A. Clinical notes. Surgical resection of pulmonary cryptococcomas in the presence of cryptococcal meningitis. J R Coll Surg Edinb. 34:1989;332-333.
94. Ghannoun M. A., Fu Y., Ibrahim A. S. In vitro determination of optimal antifungal combinations against Cryptococcus neoformans and Candida albicans. Antimicrob Agents Chemother. 39:1995;2459-2465.
95. Block E. R., Bennett J. E. The combined effect of 5-fluorocytosine and amphotericin B in the therapy of murine cryptococcosis. Proceedings of the Society for Experimental Biology & Medicine. 142:1973;476-480.
96. Jimbow T., Tejima Y., Ikemoto H. Comparison between 5-fluorocytosine, amphotericin B, and the combined administration of these agents in the therapeutic effectiveness for cryptococcal meningitis. Chemotherapy. 24:1978;374-389.
97. Larsen R. A., Leal M. A. E., Chan L. S. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. Ann Intern Med. 113:1990;183-187.
98. Utz J. P., Garrigues I. L., Sande M. A. Therapy of cryptococcosis with a combination of flucytosine and amphotericin B. J Infect Dis. 132:1975;368-373.
99. Allendoerfer R., Marquis A. J., Rinaldi M. G., Graybill J. R. Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis. Antimicrob Agents Chemother. 35:1991;726-729.
100. Larsen R. A., Bauer M., Weiner J. M. Effect of fluconazole on fungicidal activity of flucytosine in murine cryptococcal menningitis. Antimicrob Agents Chemother. 40:1996;2178-2182.
101. Larsen R. A., Bozette S. A., Jones B. Fluconazole combined with flucytosine for cryptococcal meningitis in persons with AIDS. VII International Conference on AIDS. 1991.
102. Mayanja-Kizza H., Oishi K., Mitarai S. Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clin Infect Dis. 26:1998;1362-1366.
103. Nguyen M. H., Barchiesi F., McGough D. A., Yu V. L., Rinaldi M. G. In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var neoformans. Antimicrob Agents Chemother. 39:1995;1691-1695.
104. Nguyen M. H., Yu C., Graybill J. R. Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningitis. Antimicrob Agents Chemother. 41:1997;1120-1123.
105. Just-Nubling G., Heise W., Rieg G. Triple combination of amphotericin B, Flucytosine and fluconazole for treatment of acute cryptococcal meningitis in patients with AIDS. International Conference on Cryptococcus and Cryptococcosis. abstr V5:1996.
106. Fujita N. K., Edwards J. E. Combined in vitro effect of amphotericin B and rifampin on Cryptococcus neoformans. Antimicrob Agents Chemother. 19:1981;196-198.
107. Perfect J. R., Durack D. T. Treatment of experimental cryptococcal meningitis with amphotericin B, 5-fluorocytosine and ketoconazole. J Infect Dis. 146:1982;429-435.
108. Pfaller M. A., Zhang J., Messer S. A. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob Agents Chemother. 43:1999;169-171.
109. Nguyen M. H., Yu C. Y. Comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates. Antimicrob Agents Chemother. 42:1998;471-472.
110. Clancy C. J., Yu C. Y., Nguyen M. H. In vitro activity of voriconazole against yeasts and comparison with fluconazole. 37th Interscience Conference on Antimicrobial Agents Chemotherapy, Toronto. abstr. E88:1997.
111. Perfect J. R., Cox G. M., Dodge R. K., Schell W. A. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother. 40:1996;1910-1913.
112. Hata K., Kimura J., Miki H., Toyosawa T., Moriyama M., Katso K. Efficacy of ER-30346, a novel oral triazole antifungal agent in experimental models of aspergillosis, candidiasis and cryptococcosis. Antimicrob Agents Chemother. 40:1996;2243-2247.
113. Schell W. A., Duboc D. E., Almeida G. M., Dodge R. K., Okonogi K., Perfect J. R. In vitro and in vivo efficacy of the triazole, TAK-187. Antimicrob Agents Chemother. 42:1998;2630-2632.
114. Dominguez J. M., Capa L., Serramia M. J. Translation elongation factor 2 (EF2) is the target for sordarin-derived antifungals. 37th Interscience Conference on Antimicrobial Agents Chemotherapy, Toronto. abstr. F-55:1997.
115. Sousa-Sanchez A., Alvarez M. E., Parra C., Baguero F. Activity on clinical yeast isolates of a new antifungal agent, GM 237354. 37th Interscience Conference on Antimicrobial Agents Chemotherapy, Toronto. abstr. F-56:1997.
116. Del Poeta M., Schell W. A., Dykstra C. C. In vitro antifungal activity of a series of dicationic substitute carbazoles, furans and benzimidazoles. Antimicrob Agents Chemother. in press:1998.
117. Del Poeta M., Schell W. A., Dykstra C. C. Structure-in vitro activity relationship of pentamidine analogous and dicationic substituted bis-benzimidazoles as new antifungal agents. Antimicrobial Agents & Chemotherapy. in press:1998.
118. Barchiesi F., Del Poeta M., Morbiducei V., Ancarani F., Scalise G. Effect of pentamidine on the growth of Cryptococcus neoformans. J Antimicrob Chemother. 33:1994;1229-1232.
119. Fromtling R. A., Bulmer G. S. In vitro effect of aqueous extract of garlic (Allium sativum) on the growth and viability of Cryptococcus neoformans. Mycologia. 70:1978;397-405.
120. Louria D. B., Lavenhar M., Kaminski T., Eng R. H. Garlic (Allium sativum) in the treatment of experimental cryptococcosis. J Med Vet Mycol. 27:1989;253-257.
121. Fung-Tomc J. C., Minassian B., Huczko E., Kolek B., Bonner D. P., Kessler R. E. In vitro antifungal and fungicidal spectra of a new pradimicin derivative, BMS-0181184. Antimicrob Agents Chemother. 39:1995;295-300.
122. Mody C. H., Toews G. B., Lipscomb M. F. Cyclosporin A inhibits the growth of Cryptococcus neoformans in a murine model. Infect Immun. 56:1988;7-12.
123. Mody C. H., Toews G. B., Lipscomb M. F. Treatment of murine cryptococcosis with cyclosporin-A in normal and athymic mice. Am Rev Resp Dis. 139:1989;8-13.
124. Perfect J. R., Durack D. T. Effects of cyclosporine in experimental cryptococcal meningitis. Infect Immun. 50:1985;22-26.
125. Odom A., Del Poeta M., Perfect J., Heitman J. The immunosuppressant FK506 and its non-immunosuppressive analog L-685, 818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. Antimicrob Agents Chemother. 41:1997;156-161.
126. Johnson E. M., Warnock D. W., Luker J., Porter S. R., Scully C. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidasis. J Antimicrob Chemother. 35:1995;103-114.
127. de Lalla F., Pellizzer G., Vaglia A. Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: reliability of relatively high doses administered over a relatively short period. Clin Infect Dis. 20:1995;263-266.